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Secreted and membrane tethered matrix metalloproteinases (MMPs) are key homeostatic proteases regulating
the extracellular signaling and structural matrix environment of cells and tissues. For drug targeting of proteases,
selectivity for individual molecules is highly desired and can be met by high yield active site specificity profiling.
Using the high throughput Proteomic Identification of protease Cleavage Sites (PICS) method to simultaneously
profile both theprimeandnon-primesides of the cleavagesites of ninehumanMMPs,we identifiedmore than4300
cleavages fromP6 toP6′ in biologically diverse humanpeptide libraries.MMPspecificity andkinetic efficiencywere
mainly guided by aliphatic and aromatic residues in P1′ (with a ~32–93% preference for leucine depending on the
MMP), and basic and small residues in P2′ and P3′, respectively. A wide differential preference for the hallmark P3
proline was found between MMPs ranging from 15 to 46%, yet when combined in the same peptide with the
universally preferred P1′ leucine, an unexpected negative cooperativity emerged. This was not observed in
previous studies, probably due to the paucity of approaches that profile both the prime and non-prime sides
together, and themasking of subsite cooperativity effects by global heat maps and iceLogos. These caveatsmake
it critical to check for these biologically highly important effects by fixing all 20 amino acids one-by-one in the
respective subsites and thorough assessing of the inferred specificity logo changes. Indeed an analysis of bona
fideMEROPSphysiological substrate cleavage data revealed that of the 37 natural substrateswith either a P3-Pro
or a P1′-Leu only 5 shared both features, confirming the PICS data. Upon probing with several new
quenched-fluorescent peptides, rationally designed on our specificity data, the negative cooperativity was
explained by reduced non-prime side flexibility constraining accommodation of the rigidifying P3 proline with
leucine locked in S1′. Similar negative cooperativity betweenP3 proline and the novel preference for asparagine in
P1 cements our conclusion that non-prime side flexibility greatly impacts MMP binding affinity and cleavage
efficiency. Thus, unexpected sequence cooperativity consequences were revealed by PICS that uniquelyAuthors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
rg/licenses/by-nc-nd/4.0/). Matrix Biol. (2016) 49, 37–60
38 Specificity portrayal of nine matrix metalloproteinasesencompasses both the non-prime and prime sides flanking the proteomic-pinpointed scissile bond.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Matrixmetalloproteinases (MMPs) area 23-member
family of zinc dependent and calcium containing
secreted endopeptidases in humans belonging to
the M(A) clan of metallopeptidases and the metzincin
subclan of proteases [1–5] (Fig. 1A). Initially described
as degraders of all ~300 extracellular matrix proteins
[6,7], in numerous physiological and pathological
processes [8–11], but without experimental evidence
for cleavage of most of these proteins, discovery of
indirect signaling roles was delayed as a consequence
of their name. MMPs liberate matrix protein-bound
cytokines and growth factors (e.g. VEGF and TGFβ)
from the extracellular matrix [12] and release bioactive
cryptic peptides upon cleavage of ECM proteins such
as laminin-5 and collagen IV [13–15], or matricellular
proteins such as osteopontin or SPARC [16,17].
Excellent reviews putting the spotlight on these
bioactive peptides cal led matr ikines and/
or matricryptins have been published recently
[18–20]. Following deeper analysis of the MMP
substrate repertoire, the substrate degradome, wide-
spread direct signaling roles by precision proteolytic
cleavage of diverse bioactive molecules in innate
immunity, tissue homeostasis, and pathology, is now
recognized [21–23]. Thus, proteolytic processing by
MMPs, either directly via activating or inactivating
cleavage or indirectly due to cleavage of interacting or
inhibitory proteins [24,25] also regulatesmultiple other
proteases in the protease web. Prominent examples
include: (i) upregulation of the complement cascade
and interferon-α by MMP2 [26] and MMP12 [111],
respectively, (ii) downregulation of complement by
MMP12 [27], (iii) shedding of membrane anchored
HB-EGF by MMP3 and TNF-α by MMP7 [28,29],
(iv) precise processing of stromal cell-derived factor-α
by MMP2, switching the CXCR4 ligand into a highly
neurotoxic CXCR3 binding protein [30], and
(v) pervasive regulation of leukocytes by chemokine
processing [31,32]. Thus, through precise proteolytic
processing, MMPs have pivotal roles in the regulation
of amyriadof biological pathways,both in homeostasis
and disease. Excessive MMP activation is associated
with multiple diseases yet elevated MMP activity is not
necessarily detrimental, as MMP-mediated degrada-
tion of the ECM can result in reduced fibrosis [33], and
MMPs 3, 8, 9, and 12 are protective in murine cancer
models [34,35]. Further examples highlighting the
importance of ECM remodeling and MMPs in devel-
opment and disease can be found in recent reviews[36–39], yet the higher order control of cells by
remodeling of signaling networks is suggested as the
more dominant role in vivo [21–23].
Making up the MMP family are three collagenases
(MMPs 1, 8, and 13), two gelatinases (MMPs 2 and
9), three stromelysins (MMPs 3, 10, and 11), two
matrilysins (MMPs 7 and 26), six membrane-type
MMPs, subdivided into GPI-anchored (MMPs 17 and
25) and transmembrane-type MMPs (MMPs 14, 15,
16, 24), with MMPs 12, 19, 20, 21, 23, 27, and 28
grouped together as ‘other’ MMPs [2,3,40]. Exclusive
to the two gelatinases are three fibronectin type-II-like
repeats, inserted in tandem just before the active site
(Fig. 1B), facilitating gelatin and collagen binding
[41–43]. Common to all MMPs is an extended zincin
motif HExGHxxGxxH (Supplementary Fig. 1) and the
“hydrophobic basement”-forming and name-giving
Met-turn (“Metzincin”), which is positioned underneath
the catalytic zinc. Three histidine residues and a water
molecule coordinate the catalytic zinc in the active site
crevice, which divides the catalytic domain when
viewed in standard orientation into an N-terminal
upper and a C-terminal lower subdomain [44]. Upon
substrate binding, the carbonyl group of the scissile
peptide bond coordinates with the zinc atom thus
becoming strongly polarized. The glutamate of the
active sitemotif actsas ageneral base, pulling aproton
from the zinc-activated nucleophilic water, turning it
into OH−, which subsequently attacks and directly
hydrolyzes the amide bond of the bound substrate
[1,2,4].
Knowledge of protease cleavage site specificity
is not only fundamental to the understanding of the
dynamic interactions between proteolytic enzymes
and their substrates, but is also a prerequisite for
the design of sensitive and specific activity assays
and the development of inhibitory drugs [45–47].
With liquid chromatography–tandem mass-spec-
trometry (LC–MS/MS) being among the most
sensitive methods to resolve and detect complex
peptide mixtures, the combination of peptide
libraries with mass spectrometry was the rational
next step for accurate active site protease speci-
ficity profiling. This approach suffered from the low
success of de novo sequencing of highly redundant
synthetic peptide sequences; however, this prob-
lem was solved using peptide libraries generated
from fully sequenced species that enabled use of
the conventional proteomic search engines for
peptide spectral matching [48,49]. This improve-
ment underpins the high throughput Proteomic
39Specificity portrayal of nine matrix metalloproteinasesIdentification of protease Cleavage Sites (PICS)
method, which uniquely determines both the prime
and non-prime cleavage site preferences in a
single experiment: prime side sequences are
identified by LC–MS/MS and the corresponding
non-prime side sequences are derived bioinforma-
tically by database searches. PICS uses diverse,
proteome-derived, and database-searchable pep-
tide libraries generated by highly specific
endoproteinases, typically trypsin, chymotrypsin,
or Staphylococcus aureus protease V8 (GluC),
allowing highly sensitive and unbiased active site
specificity profiling using these denatured peptides
[48,49]. For in depth profiling, complementary
libraries differing in their C-terminal amino
acid residues are used, as for example GluC-gen-
erated peptide libraries lack internal acidic residues,
and tryptic PICS libraries are devoid of basic
residues. Thus, PICS allows active site specificity
profiling without any prior knowledge of the physi-
ological role, structure, or sequence preference of
the tested protease. Alignment of hundreds
of identified individual cleavage sites subsequently
provides an unbiased and detailed picture of the
amino acid sequences flanking the scissile peptide
bonds, thus allowing the generation of a robust
proteolytic signature of numerous proteases [50–
54]. Unlike other approaches profiling just the prime
or non-prime side, or using positional scanning,
spatial information is retained in the cleaved
peptides of a PICS experiment enabling detailed
cooperativity analyses to be performed. Like all
denatured peptide library-based approaches, PICS
data cannot be reliably used for native substrate
identification and ignores exosite interactions on
distant or proximal domains due to constraints of
peptide length used in the assays. Rather its utility
resides in active site profiling in a unique manner
from P6 to P6′ that can be used for assay
development and drug targeting.
Matrix metalloproteinases specificity is guided
by positional preferences, both N-terminal (non--
prime side) and C-terminal (prime side) to the
scissile peptide bond. Hence PICS is well suited
for an unbiased comparison of specificity determi-
nants within the MMP family. In this study, we
present a family-wide specificity portrait of nine
human matrix metalloproteinases determined by
PICS representing the largest specificity profile for
any protease family to date spanning P6 to P6′. We
assayed all secreted collagenases (MMPs 1, 8,
and 13), both gelatinases (MMPs 2 and 9), one
representative member of the stromelysins
(MMP3) and matrilysins (MMP7), membrane-type
MMPs (MMP14), and macrophage MMP12, to
obtain a comprehensive picture of their active
s i t e p re fe rences and an imos i t i e s , and
corroborated the results with in-depth structural
and synthetic peptide cleavage analysis.Results
Substrate specificity profiling using PICS
We identified more than 2800 cleavage sites using
tryptic libraries and over 1500 using GluC-generated
peptide libraries, giving a median of 439 identified
cleavages for each MMP analyzed (Fig. 1C; Supple-
mentary Tables 1 and 2). A minimum of 128 (MMP8;
GluC-generated peptide library) and amaximumof 699
(MMP2; trypsin-generated peptide library) cleavages
were identified. Importantly, trypsin-generated peptide
libraries typically yield 2–3 times higher cleavage
numbers since semi-tryptic peptides with their C-termi-
nal basic residue are more amenable to mass
spectrometry than GluC-generated peptides. Note,
the number of identified cleavages does not necessar-
ily correlate with enzyme activity but rather reflects
instrument performance on the day of MS-analysis.
Global specificity features shared by most MMPs were
determined as well as distinguishing features charac-
terizing individual MMPs or MMP sub-groups. We
summarized their individual subsite specificities asheat
maps and iceLogos in Figs. 2 and 3 (trypsin-generated
PICS libraries) and Supplementary Figs. 2 and 3 (GluC
libraries). Overall, all MMPs showed comparably
similar specificity profiles with some subsites being
more important or discriminating than others. Notably,
specificity was mainly guided by aliphatic and aromatic
residues in P1′ followed by a pronounced preference
for proline in P3, the two well recognized specificity
features of MMPs [2,55]. Although all tested MMPs
adhered to this general specificity profile (Figs. 4 and5),
there are numerous features that distinguish individual
MMPs, which were further elaborated using a panel of
quenched fluorescence peptides (Fig. 6). Below, we
discuss both shared and distinguishingMMPspecificity
determinants for the positions P3 to P3′. With the
exception of acidic and basic residues, which can be
only investigated in tryptic or GluC-generated libraries,
respectively, we focused on features present within
both libraries that were thus individually validated by
separate library classes.Of note, as can be seen by the
agreement for all MMPs of the individual specificity
determination heat maps using tryptic (Figs. 2 and 3,
Supplementary Table 1) and GluC (Supplementary
Figs. 2 and 3, Supplementary Table 2) libraries, this
data concordance highlights the robustness and
reproducibility of PICS.
Subsite P3
Although the P3 preference for proline is a hallmark
feature of theMMP family, we found awide differential
preference for proline. MMPs 9 and 13 displayed
the highest prevalence of P3 proline (46 and 35%,
respectively). On the other hand, MMPs 7 (15%), 12
(17%) and 14 (15%) displayed a comparably low
Fig. 1 (legend on next page)
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41Specificity portrayal of nine matrix metalloproteinasesproline preference as assayed by both tryptic and
GluCPICS libraries. MostMMPs also favored small to
large aliphatic residues in P3, such as alanine, valine,
isoleucine, and leucine, with a combined frequency
ranging from 32% (MMP9) to 46% (MMP3).
Subsite P2
Specificity profiles that we obtained were fairly
diverse at P2 within the MMP family. For most MMPs,
the presence of acidic residues in P2 co-occurred
with an increased presence of proline in P3, an effect
that was also observed for basic residues in MMPs 8
and 14. Most, but not all, MMPs displayed a certain
preference for small residues such as alanine or
glycine, most prominent for MMPs 2 and 3 (N34%),
whereas MMP1 (14%) and MMP8 (12%) selected
larger residues, such as leucine, phenylalanine,
tyrosine and glutamine (N36%). For 7 out of the 9
MMPs we detected noticeable P2 selectivity for
charged residues: Whereas MMPs 1, 7, 8, 12 and
14 possessed partial preference for acidic but not
basic residues, MMPs 9 and 13 selected positively
charged residues as noted before [56–59]. Interest-
ingly, preferences towards acidic and basic residues
in P2 seemed to be not necessarilymutually exclusive
since several MMPs, most prominently MMP12,
readily accommodated both amino acid classes.
However, MMPs with a strong preference for small
residues (MMPs 2 and 3) did not, or could not, show a
concurrent preference for charged residues; these
two features appeared to be mutually exclusive, but
supposedly more due to the size than the physico-
chemical properties of charged amino acids. The
selectivity ofMMP9 for basic residues inP2 is linked to
an aspartic residue (Asp410) in proximity to S2 [56],
likely forming a salt bridge; its gelatinase counterpart
MMP2 possesses a bulkier glutamic residue at the
structurally equivalent position, narrowing the subsite
and inducing the preference for small residues in
MMP2 [56]. A similar effect was seen for MMP3,
where the structurally equivalent residue Phe227 fills
up nearly the entire subsite, and thus restricts it to
small aliphatic residues (see Figs. 7 and 8).Fig. 1. (A) Schematic representation of the protein structure
PD prodomain, TM/C transmembrane/cytoplasmic domain. T
peptide, prodomain, whereas archetypical MMPs (e.g. MMP1)
the catalytic domain by a linker, and membrane-type MMPs a
cytoplasmic domain (e.g. MMP14) or a GPI-anchoring sequenc
and 9 harbor three supplementary collagen binding fibronecti
Topology diagram of an MMP catalytic domain with sequen
complemented by ribbon representations of the prodomain, t
domain. (C) Coomassie brilliant blue-stained SDS-PAGE ana
each MMP were loaded together with PiNK plus prestained p
60 kDa for MMP1, MMP13 and MMP14 result from heterogen
Hpx-domain truncated isoform was also detected (band at app
numbering used throughout the manuscript (starting at Met1)
the following off-sets to account for loss of the respective signa
MMP8: -20, MMP9: -19, MMP12: -15, MMP13: -19, and MMPSubsite P1
We identified a two to four-fold enrichment for
asparagine in P1 for all tested MMPs, a preference
previously only described for MMP2 [48]. Additional
preferences included small amino acids such as
glycine, alanine or serine, which was particularly
strong inMMPs2, 9, 13 and 14,whereas aromatic and
larger aliphatic residueswerebarely observed inP1. A
modest preference for acidic residues was identified
for severalMMPs,most frequently inMMPs3, 7, 8 and
12, so logically reducing their preference for small
amino acids here. The opposite was found for MMPs
2, 9, and 14, which showed a strong preference for
small, but not for acidic amino acids. The strong
preference for acidic residues in P1 by MMP3, but not
MMPs 1 and 9, is corroborated by previous specificity
studies [60,61], and is thought to mediate efficient
MMP3 cleavage of substrates not effectively targeted
by other MMPs [62]. Interestingly, preferences for
basic and acidic residues are once again not mutually
exclusive, but occur alongside each other, most
apparent in the profiles obtained for MMP7, implying
hydrogen bonding rather than salt bridging.
Subsite P1′
P1′ leucine clearly constituted the primary specificity
determinant for allMMPsprobed in this study. Together
with isoleucine, and to a lesser extent valine and
methionine, a combined occurrence of 60% (MMP13)
to 93% (MMP7)was observed. In good agreementwith
previous studies [61], MMP7 was differentiated from
the other MMPs by displaying the highest leucine
preference (62%), whereas MMPs 3, 9, 12 and 13
showed the lowest frequency (32–33%). Some MMPs
also displayed a modest preference for large aromatic
residues, prominently seen for MMP8 and to a slightly
lesser extent forMMPs3, 12, 13, and14. This feature is
confirmed by a study using mixture-based oriented
peptide libraries [55] showing a moderate preference
for aromatic residues, that, though not exceeding the
natural abundance by more than 2.5 fold, still indicates
a comparably deeperS1′pocket. In PICS,MMPs8ands and arrangements of the MMP family. SP signal peptide,
he minimal MMPs 7 and 26 have an N-terminal signal
also carry a four-bladed hemopexin C domain attached to
lso have a stalk domain and either a transmembrane and
e (e.g. MMP17) at their C-terminus. The gelatinases MMP2
n-like type II domains inserted in the catalytic domain. (B)
ce numbering according to MMP1 (UniProt ID: P03956),
he fibronectin-like type II domains, and the hemopexin C
lysis (15% gels) of all MMPs used in this study. 1–2 μg of
rotein ladder (GeneDireX). Doublets visible around 50 to
eous glycosylation, and for soluble MMP14 (sMMP14) the
rox. 28 kDa). Of note, to convert the UniProtKB sequence
to traditional numbering of secreted proMMPs, please use
l peptide: MMP1: -21, MMP2: -29, MMP3: -17, MMP7: -17,
14: -28.
42 Specificity portrayal of nine matrix metalloproteinases13 showed more than 2.3-fold enrichment for tyrosine
and tryptophan, respectively, whereas MMPs 12 and
14 enriched for both phenylalanine and tryptophan to a
similar extent. This limited preference is also supported
by other specificity studies using synthetic peptides
[63,64]. Notably, our study also included two MMPs
annotated as having small S1′ pockets, namely MMPs
1 and 7 [65], and indeed in both cases all aromatic
residues remained with a combined occurrence of 2.9
and 3.5%, clearly below their natural abundance of
7.4%. Unexpectedly, a weak P1′ preference for
glutamine was observed for MMPs 9, 12 and 13, a
feature entirely absent in MMPs 1 and 7, whereas
MMPs 3, 9 and 13 displayed a noticeable preference
for carbamidomethylated cysteine introduced during
PICS library preparation, most likely due to its aliphatic
property. Of note, a recently established differentiating
feature between collagenases and gelatinases [66],
namely a low P1′ frequency of leucine in gelatinases,
could not be verified in our study.
SinceP1′ leucine andP3proline constitute themajor
MMP specificity determinants, we systematically
probed subsite cooperativity for these two features
(Supplementary Table 3): To our surprise, all MMPs
displayed negative subsite cooperativity for P1′
leucine and P3 proline. For example, in the case of
MMP13, the occurrence of P3 proline decreases from
34.8% (all cleaved peptides) to 20.2% (cleaved
peptides with P1′ leucine) while the occurrence of P1′
leucine decreases from33.2% (all cleaved peptides) to
19.3% (cleaved peptides with P3 proline). This effect
was least pronounced in MMPs 1 and 2. Importantly,
subsite cooperativity is easily detected by the PICS
assay but cannot be assessed by global heat maps or
iceLogos — a frequently ignored or underestimated
caveat, that needs thorough individual assessment of
all subsites and amino acids.
Subsite P2′
In P2′, MMP specificity was dominated by a
preference for isoleucine and valine (average occur-
rence of 23%) together with a preference for positively
charged amino acids (19%). The latter feature was
detected mostly in GluC libraries since tryptic libraries
have lysine and arginine only at the C-terminus of
the peptide. Corroborated by a previous study [55], a
distinct preference for basic residueswas identified for
all MMPs; whereas it wasmost prominent for MMP12,
it appeared to be of lesser importance for MMPs 1, 2,Fig. 2. PICS sequence specificity profiles of MMPs 1, 2, 3,
Identified cleavage sites (n values shown) are summarized as h
more incisive fold-change over the natural abundance of amin
difference compared to natural amino acid abundance (right pa
plotted amino acids are indicated on the y axes with one-lette
acids are shown above the x axis, under-represented residue
identified are depicted in pink. For easier comparison, the samand 8. For MMP9, a comparably low occurrence of
basic residues in the GluC profile was counter-
balanced by a notable overrepresentation of histidine
in the tryptic profile. Of note, the arginine preference
we identified in P2′ for MMP12 perfectly correlates
with its unusual processing and inactivation of the
ELR+ neutrophil chemokines within the E↓LR site,
which is not observed for other MMPs [67]. The
preference for medium-sized aliphatic residues such
as valine and isoleucine was more evident with tryptic
PICS libraries, most likely as this feature is supersed-
ed by the pronounced MMP preference for basic
residues in GluC libraries, illustrating the benefit of
using more than one peptide library type for compre-
hensive active site specificity profiling.
Subsite P3′
P3′ selectivity appeared to be as inconsistent as
that of P2 across the MMP family and thus could be
of similar importance as P2 for the specific targeting
of individual family members as previously sug-
gested [64]. Most MMPs showed a marked prefer-
ence for small amino acids such as glycine and
alanine, with a combined average occurrence of 31%.
This preferencewasmost pronounced forMMPs8and
9 (N44%), and least forMMP14 (20%).Notably,MMPs
1 and 8 showed preferences for acidic residues, but
not basic residues, whereasMMPs 3, 7, and 12, and to
a lesser extent MMPs 13 and 14 selected both. As
seen for P2 andP1, the preference for basic and acidic
residues was not mutually exclusive. A minor prefer-
ence for valine or isoleucine was identified for MMPs 1
and 14, and most MMPs readily accommodated
hydrophilic residues, even though no individual MMP
emerged as having a particularly strong hydrophilic
preference. Finally, the sequence diversity identified in
this study is in strong agreement with the structural
description of the S3′ site as being of both hydrophobic
and polar in nature [65].
Shared features in the MMP specificity profile
Toobtain aglobal viewof the common featuresof the
MMP family active site specificity profile, we created
heat maps comparing the 9 MMPs at the individual P3
to P3′ positions (Fig. 4), and a composite heatmap and
iceLogo using a total of 1800 cleavage sites, randomly
selected, 100 per MMP for each peptide library
(Fig. 5A). Both representations were dominated by7, and 8 using trypsin-generated human peptide libraries.
eat maps showing relative occurrence (left panels) and the
o acids (middle panels) and as iceLogos, showing percent
nels). P6 to P6′ subsite positions are shown on the x axes;
r codes. In iceLogos, significantly over-represented amino
s below the x axis, and amino acids that have not been
e scales have been applied to all MMPs.
Fig. 2 (legend on previous page)
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Fig. 3. PICS sequence specificity profiles of MMPs 9, 12, 13, and 14 using trypsin-generated human peptide libraries.
Identified cleavage sites (n values shown) are summarized as heat maps showing relative occurrence (left panels) and the
more incisive fold-change over the natural abundance of amino acids (middle panels) and as iceLogos, showing percent
difference compared to natural amino acid abundance (right panels). P6 to P6′ subsite positions are shown on the x axes;
plotted amino acids are indicated on the y axes with one-letter codes. In iceLogos, significantly over-represented amino
acids are shown above the x axis, under-represented residues below the x axis, and amino acids that have not been
identified are depicted in pink. For easier comparison, the same scales have been applied to all MMPs.
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Fig. 4. Side-by-side comparison of MMP cleavages in human (A) trypsin- and (B) GluC-generated peptide libraries.
Identified cleavage sites were summarized as heat maps showing fold-change over the natural abundance of amino acids
for each P3 to P3′ position. The same scales have been applied to all MMPs.
45Specificity portrayal of nine matrix metalloproteinasesthe two hallmark specificity features of MMPs, proline
in P3 and Leu/Ile in P1′. Other than proline, only
alanine, valine, and isoleucine were readily accommo-
dated inP3andshowedenrichment above their natural
abundance. In contrast, P2 displayed a much higher
diversity, but as these individual preferences cancel
each other out in the combined analysis, only alanine
remained as the common denominator. Notably, Pro
was nearly entirely missing in P2. Surprisingly, in P1,
asparagine stood out in both libraries with an overall
3-fold enrichment, whereas valine, isoleucine, and
leucine were all diminished N2-fold. All tested MMPs
showed at least a 2-fold enrichment for asparagine,
whereas only 4 reached this threshold for the nextmost
prevalent P1 features. Due to the high prevalence of
leucine and isoleucine in P1′, only 6more amino acids,
cysteine, glutamine, methionine, phenylalanine,
tryptophan, and valine stayed above their natural
abundance in the combined analysis, yet not reaching
2-fold enrichment. In position P2′, three residues
emerged as common preferences: valine, isoleucineand lysine were all enriched N2-fold in 8 out of
the 9 MMPs in tryptic and GluC libraries, whereas
aspartate, glutamate, and proline were more than
3-fold underrepresented. Similar to P2, P3′ displayed
a rather divergent picture with small hydrophobic
residues such as glycine, alanine, and valine being
the only mutuality with an average 2-fold enrichment.
Intrigued by the negative cooperativity between
P3-Pro and P1′-Leu, we downloaded all high confi-
dence MEROPS curated [68] native substrates of
MMPs 1, 2, 3, 7, 8, 9, 12, 13 and 14; i.e. substrates with
cleavage sites verified by N-terminal sequencing.
These corresponded to 112 redundant (i.e. more than
one MMP cleaved at the same site) and 79 non-
redundantP6–P6′ cleavages (SupplementaryTable 4).
Analysis of the cleavage specificity profiles of the
native substrates from MEROPS (Fig. 5B) was
remarkably similar to the PICS proteomic analyses
(Fig. 5A). Interestingly, even though half of the native
substrates had either proline in P3 or leucine in P1′
(Supplementary Table 4 and Fig. 5E), only 5 (6.3%)
Fig. 5 (legend on next page)
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corroborating the PICS negative cooperativity results.
MMP7 cuts two of these substrates possessing both
P3-Pro and P1′-Leu, both syndecans. Just as other
proteases have substrate-binding exosite domains
[41,69] that enhance chances of substrate cleavage,
MMP7, which lacks a C-terminal hemopexin domain,
binds to glycosaminoglycan side chains which likely
facilitates cleavage of these otherwise less preferred
sites [70].
Additionally, when we compared the collagenase
specificity profiles (Fig. 5C) with the gelatinase
specificity profiles (Fig. 5D), only small divergences
emerged. Whereas the occurrence of P3-Pro was
significantly lower in collagenases compared to in
gelatinases (21.9% vs. 36.1%), the opposite was
the case for P1-Asn (13.6 vs. 5.2%), but this was
partly compensated by higher occurrences of aspar-
tate, glutamate, and glutamine in the gelatinases
(14.7 vs. 19.7%). Of note, even though the iceLogo
representation indicated a higher P1′ promiscuity
for collagenases, the combined occurrence of
carbamidomethylated cysteine, methionine, valine,
and glutamine (10.5 vs. 10.4%) and the occurrences of
the dominating leucine (39.7 vs. 37.4%) and isoleucine
(14.7 vs. 16.4%)were highly similar in both sub-groups
(Fig. 5C and D).
Refining MMP specificity profiles by quenched
fluorescent probes and in silico peptide docking
The quenched fluorescent (QF) peptide QF-24 is
the classical and long-used MMP substrate, origi-
nally designed based on the loose consensus of
the collagen type I cleavage site by MMPs, PLG↓L
[71]. QF-24 Mca-PLG↓L-Dpa-AR-NH2 is C-terminally
amidated and carries the fluorophore (Mca) and
quencher (Dpa) with a penultimate arginine for
improved solubility. Based on shared features of the
9 MMPs in their specificity profiles (Figs. 4 and 5) we
designed a new quenched fluorescent peptide:
Mca-PAN↓L-Dpa-AR-NH2 (Fig. 6A). To probe for
the individual subsite preferences of each MMP we
interchanged the respective P2 and P1 positions in
PLG↓L and PAN↓L to give PLN↓L and PAG↓L in twoFig. 5. (A) Consensus MMP cleavage site in human trypsi
were randomly selected for each MMP and library (total of 1
cleavage sites. (B) Consensus MMP specificity profile iden
sequencing evidence documented in MEROPS for MMPs 1, 2
downloaded (accessed on 03/09/2015), corresponding to 79
(MMPs 1, 8, 13, and 14 left) and (D) gelatinase (MMPs 2 and 9)
using trypsin- and GluC-generated peptide libraries. The corres
cleavage sites were summarized as a heat map showing fold
iceLogo displaying the percentage difference of amino acid f
proteome reference set. (E) MEROPS curated physiological M
P3-Pro or P1′-Leu. 112 native cleavages corresponding to 79 n
further analyzed; of these, 23 had leucine in P1′ (29.1%) and
hallmark features (6.3%), in perfect agreement with the negat
PICS. For more details, please refer to Supplementary Tablemore QF-peptides. We also tested the importance of
Pro in P3 by its replacement with valine: VLG↓L and
VAN↓L. All QF-peptides were C-terminally amidated,
carried the same fluorophore and quencher, and were
obtained from the same commercial vendor at the
same purity (N95%). This consistency allowed for side-
by-side comparison in quenched fluorescence cleav-
age assays (Fig. 6B and C). To aid data interpretation,
we performed in silico docking [72] with the two
heptapeptides APLG↓LLA and APAN↓LLA for all
analyzed MMPs (Figs. 7 and 8). These MMPs showed
similar active site geometries but with subtle differ-
ences, pronounced in the subsiteS2,which is relatively
shallow in the case ofMMPs3and13and thus strongly
selects small amino acids such as glycine, alanine, or
serine, but represents a deep pocket in MMP1 and 8
allowing the accommodation of large amino acids such
as tyrosine, in perfect accordance with our PICS data.
Importantly, each peptide showed different cleavage
rates for two or more MMPs that guided our structural
interpretation of their cleavage properties as related to
the specificity profile for each MMP.Discussion
By the simultaneous identification of both the prime
and non-prime active site specificity determinants that
PICS uniquely profiles, our global proteomic analysis
of over 4300 cleaved, biologically diverse peptides by
nine important representative members of the MMP
family is the most robust family-wide specificity profile
reported to date for any protease family. Analysis of
shared versus selective specificity features by PICS
revealed unexpected negative cooperativity between
the P3 proline and the P1′ leucine or isoleucine, which
are archetypical hallmark preferences for most, if not
all MMPs. Of note, global specificity analysis using
heat maps and iceLogos does not identify subsite
cooperativity effects which instead need individual
assessment by fixing all 20 amino acids one-by-one in
the respective subsites and thoroughmonitoring of the
specificity logo changes. We confirmed the negative
cooperativity between the P3 proline and P1′ leucine
identified here with denatured biologically relevantn and GluC peptide libraries. 100 unique cleavage events
800 sequences) and represented 1123 unique P6-to-P6′
tified by analyzing all native substrates with N-terminal
, 3, 7, 8, 9, 12, 13, and 14. A total of 112 cleavages were
non-redundant P6–P6′ cleavage sites. (C) Collagenase
active site specificity profiles obtained by PICS proteomics
ponding data from (A) were used for analysis. All identified
-change over natural abundance and by a corresponding
requencies between the experimental set and the human
MP substrates with N-terminal sequencing evidence and
on-redundant P6–P6′ cleavage sites were downloaded and
19 proline in P3 (24.1%), but only 5 exhibited both MMP
ive cooperativity effect of P3-Pro and P1′-Leu identified by
4.
Fig. 6 (legend on next page)
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curated native MMP substrates with N-terminal
sequencing evidence possessing either one or both
a proline at P3 and a leucine at P1′. However, this was
not noted in a very recent profiling paper [73].
Also emerging from this analysis was the novel high
preference for asparagine inP1byall analyzedMMPs.
Small amino acids in P2 were common as were acidic
or small aliphatic residues in P1 that contrasted with
the basic and aliphatic residue preferences in P2′.
Predominantly small residues in P3′ were favored
despite the distance of S3′ from the scissile bond in a
more open section of the active site cleft. From these
analyses we rationally designed two new QF-peptide
substrates that showed improved specificity for three
MMPs (MMPs1, 2 and 3) over the conventional QF-24
peptide substrate: PLN↓L is cleaved 2.5 times faster
by MMP1, whereas PAG↓L is cleaved ~2-fold faster
by MMP2 and 25% faster by MMP3. Thus, our proteo-
mic analysis strongly upholds the concept that for
MMPs, like other metzincins, P1′ is the defining
subsite in substrates unlike P1 for most serine and
cysteine proteases [63,65].
Proline and aliphatic residues that we identified as
P3 specificity determinants are supported by data
frommixture-based oriented peptide libraries [55] and
structural studies [65] emphasizing the predominantly
hydrophobic S3 pocket. A protein-centric substrate
screen for MMP9 [74] and phage display profiling of
MMP13 [59] also support the P3 proline preference,
but a lowP3 proline preference is credited as a unique
MT-MMP feature [66]. Unexpectedly we found that a
proline in P3 markedly reduced the occurrence of the
other major specificity residue, leucine in P1′. Thus,
979 cleaved peptides with a P3 proline and 1714 with
a P1′ leucine were identified, but in combination as
Pxx↓L, only 295 sequences were found. Although a
loss of flexibility in the scissile bond may reduce the
dual preference for Pxx↓L, this is not themain reason.
Indeed, of the Pxx↓L peptides cleaved, only 49 were
PxG↓Lwith other small residues also contributing to a
similar degree, e.g. 58 PxA↓L and 39 PxS↓L.
However, glycine renders the non-prime side back-
bone more flexible to accommodate a rigidifying
proline at P3 in combination with a locked-in leucine
at P1′, and this dominates over the positive selective
pressure for other residues that are on average more
preferred at P1 than glycine. Thus, although eight of
nine MMPs prefer asparagine at P1, seven showed
improved cleavage kinetics for peptides with a P1Fig. 6. (A) Schematic representation of two quenched fluore
Gly↓Leu-Dpa-Ala-Arg-NH2 (PLG↓L), and right: Mca-Pro-Al
carried N-terminal Mca ([7-methoxycoumarin-4-yl]acetyl) as the
nopropionyl]) in P2′ with the quencher dinitrophenyl (DNP), and
activity against a set of six different QF-peptides. (C) Comparison
substrate. Experiments were performed in duplicates and repeat
and were within 10% (except for MMP7 and VLG↓L).glycine and P1′ leucine. Indeed, only 138 peptides with
an Asn↓Leu scissile bond were cleaved by MMPs
other than MMP1. The exception, MMP1, was most
unexpected in displaying a strong 2.5-fold preference
for the new QF-peptide PLN↓L compared to the
common QF24 (PLG↓L), which was actually designed
from the MMP1 Gly↓Leu α2 (I) collagen cleavage site
[71], yet is highly consistent with its PICS profile (Fig. 2
and Supplementary Fig. 2).
As expected from past studies of the general MMP
substrate QF-24, PLG↓L outperformed the other
new QF-peptides for 5 out of the 9 MMPs (MMPs 7,
8, 9, 12, and 14). As predicted, we found our new
rationally designed peptide, PAG↓L, was kinetically
preferred by the other MMPs 2, 3, and 13. Only MMP3
preferred thePAN↓L sequence to the classical PLG↓L
sequence, but this is to be expected as PAN↓L
matches the MMP3 preference at all four residues
from the iceLogo of the pooled PICS cleavage sites. In
contrast, the remaining MMPs (7, 8, 9, 12, 13 and 14)
have only two or three exactly matching residues in
their iceLogos to the PAN↓L residues. Thus, PICS-
generated specificity logos represent potential cleav-
age sites rather than necessarily preferred ones. For
example, none of the identified cleavage sites in PICS
had the sequence PAN↓L, and even the general
substrate sequence PLG↓L was only found twice in 18
experiments in total.Moreover, key examples in natural
substrates show that non-preferred residues, even
those requiring active site remodeling to accommodate
large hydrophobic side chains, can be selected across
species. An overlooked example of this disproves the
universally stated notion that the shallow S1′ pocket
MMPs 1 and 7 can only accommodate small residues,
yet the P1′ residue of their own propeptides that are
autocatalytically cleaved are phenylalanine and tyro-
sine, respectively. Hence, designing a universal
general MMP peptide substrate from averaged spec-
ificity features of 9 MMPs is not feasible as individual
features of each protease dominate and must be
considered in the design of optimal cleavage assays for
individual MMPs and likely too for other proteases.
Whereas PLG↓L generally outperformed PAN↓L,
the corresponding peptide pair with valine in P3
showed the opposite; VAN↓L exceeded VLG↓L in all
MMPs, but not MMP7, and outperformed PAN↓L in
four MMPs or had no significant difference for three
MMPs. Compared to 156 different peptides cleaved at
N↓L, 211 were cleaved at G↓L. Although this might
indicate that a more flexible scissile bond is preferredscent (QF) peptides used in this study. Left: Mca-Pro-Leu-
a-Asn↓Leu-Dpa-Ala-Arg-NH2 (PAN↓L). All QF-peptides
fluorophore, had Dpa ([N-3-[2, 4-dinitrophenyl]-L-2,3-diami-
were C-terminally amidated. (B) Overall comparison of MMP
ofMMP activities normalized to the preferred peptidic MMP
ed three times. Standard deviations are given in parenthesis
Fig. 7 (legend on next page)
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tween proline in P3 and asparagine in P1 in the PICS
data. When asparagine was in P1, co-occurrence with
alanine, valine, isoleucine, and leucine in P3 was
similar to that of proline (10–15% each), whereas
with glycine in P1, even though the combined co-
occurrence of alanine, valine, isoleucine, and leucine in
P3 stayed high (44%), proline increased more to 31%.
Thus, there is cooperativity between having a rigid
proline in P3and a flexible glycine at P1—without aP3
proline, asparagine preferences can resume. Indeed, if
proline is in P3 (PxN↓x) cleavage drops to 56 out of the
4373 cleaved peptides in total and with PxN↓L, only 7
peptides were cleaved by all MMPs. However, when
proline in P3 is in combination with glycine in P1, this
negative cooperativity is completely lost, supporting
our conclusion that non-prime side flexibility impacts
binding affinity and cleavage efficiency.
This surprising negative cooperativity between two
averaged preferred residues at P3 and P1 can be
partly explained by a tyrosine (MMPs 2, 3, 7, 9, and 13)
or histidine (MMP12) residue in the upper rim of the
catalytic cleft that normally builds up the S3 subsite
roof.However, as seen in theMMP13crystal structures
2d1n and 2d1o [75], this residue can alternatively cap
the S1 subsite, making the co-occurrence of proline
in P3 and asparagine in P1 exclusive, as beneficial
binding interactions can be only provided for one of the
two sites. Even though glycine cannot provide any
specificity-guiding side-chain interactions, its flexibility
seems to be beneficial to accommodate the non-prime
side backbone that is rigidified by proline in P3,
especially when the substrate latches with large
hydrophobic residues such as leucine in S2 and S1′.
Furthermore, the glycine-conferred higher flexibility of
the scissile bond may facilitate the transition to the
tetrahedral cleavage intermediate, and thus may
indirectly increase substrate turnover rates.
Even though the collagenase MMPs 1, 8, 13 and 14
preferred PLN↓L, PLG↓L, PAG↓L, and PLG↓L,
respectively, no MMP tested, not even the collage-
nases and gelatinases, preferred leucine in P2 in the
PICS cleavage data, yet this is what is present in the
classic QF-24 PLG↓L substrate. Besides the similar
negative selection of both gelatinases against leucine
in P2, only MMP2 favored the exchange to alanine,Fig. 7. (A) Ribbon and surface representation of the MMP1
S2′ subsites. The catalytic zinc located in the catalytic groove a
sheet are shown as yellow spheres, calcium ions are depicted i
Met-turn are shown as sticks, the active site water is shown as
in red, with the active-site-facing edge strand in orange. The act
are colored in blue. The insertion site of the three fibronectin
(B) In-silico docking of MMPs 1, 2, 3, 7 and 8 with two model h
The catalytic zinc is depicted as a yellow sphere. Docked p
representation with overlaid electrostatic surface potentials (reindicating a larger hydrophobic pocket in MMP9. A
comparable preference for alanine over leucine in P2
was additionally only seen in MMPs 3 and 13, most
likely due to their rather shallow S2 subsites (Figs. 7
and 8). Cleavage of these QF-peptides also revealed
differentiating features within the collagenases. Con-
trary to MMP13, MMPs 1, 8 and 14 preferred leucine to
alanine in P2 in theQF-peptide substrates. However, in
both tested scenarios onlyMMP1preferred asparagine
to glycine in P1 — most likely due to beneficial polar
contacts arising from the upper rim residue Asn180.
This feature is not present in any of the other tested
MMPs (Supplementary Fig. 1), which possess large
hydrophobic residues such as leucine, isoleucine, or
phenylalanine at the equivalent position. However, in
MMP7, the equivalent polar threonine nonetheless is
inadequate in length to stabilize asparagine in P1,
which is therefore not preferred. Finally, the non-prime
side of MMPs is structurally open, especially compared
to the more narrow prime side. Thus it seems essential
for cleavage efficiency that peptides fully occupy theS2
site so as to bring up the preceding residue to the S3
subsite and to achieve antiparallel alignment of the
substrate to the active site facing edge strand of the
five-stranded β-pleated sheet of the MMP catalytic
domain (Figs. 1B and 7A). In several MMPs this is only
possible with large hydrophobic residues, typically built
up by two aromatic rings (e.g. Y182 and F195 in
MMP2).
It is also important to keep in mind that PICS and
QF-peptide cleavage assay results are independent
and only conditionally interchangeable. This reflects
a strength of PICS, as by allowing low affinity
substrates to be turned over with time, a biologically
more relevant picture is obtained such as for those
natural protein substrates that depend on exosite
interactions to promote cleavage of less preferred
scissile bonds. This was shown conclusively in
protein engineering studies of preferred versus less
preferred cleavage sites engineered on protein
backbones that either bind a substrate binding
hemopexin exosite versus a homologous substrate
nonbinding hemopexin domain [69]. This means
that by PICS, which analyzes peptide cleavage in
the absence of exosite interactions with protein
substrates, these features do not mutually select forcatalytic domain in standard orientation showing the S3 to
nd the structural zinc located on top of the five-pleated beta
n red. Proteinaceous zinc ligands and the methionine of the
a blue sphere. The central five-stranded β-sheet is colored
ive-site helix is shown in magenta whereas all other helices
-type II domains in MMPs 2 and 9 is indicated in yellow.
eptapeptides, A-PLG↓L-LA (left) and A-PAN↓L-LA (right).
eptides and MMPs are shown in stick mode and surface
d: negative; blue: positive), respectively.
Fig. 8. In-silico docking of MMPs 9, 12, 13 and 14, with two model heptapeptides, A-PLG↓L-LA (left) and A-PAN↓L-LA
(right). The catalytic zinc is depicted as a yellow sphere. Docked peptides and MMPs are shown in stick mode and surface
representation with overlaid electrostatic surface potentials (red: negative; blue: positive), respectively.
52 Specificity portrayal of nine matrix metalloproteinaseseach other. Rather, they allow otherwise less
preferred cleaved sequences to be identified, thus
generating large numbers of cleavage sites on
which robust statistical analyses can be performed.
For instance, the two hallmark MMP specificity
features P3 proline and P1′ leucine emerged with
unexpected negative cooperativity. Yet the pres-ence of both features can still result in a peptide
exhibiting favorable cleavage kinetics. Moreover,
in a living cell, cleavage does not just rely on a
perfect cleavage sequence, but rather on substrate
recognition and accessibility of the respective site
due to structural considerations, which denatured
peptide and synthetic peptide libraries do not
53Specificity portrayal of nine matrix metalloproteinasesreplicate. Thus, even though a certain amount of
complementarity of the sequence surrounding the
scissile peptide bond and the active site is a
prerequisite for cleavage, it is still only one piece
in the complex interplay between proteases and
their substrates. Indeed, less preferred cleavage
sites can be selected for that lead to slow cleavage
events which can be a centerpiece of biological
control, to dampen sudden oscillations.
The present analysis represents the largest robust
specificity profile of a protease family to date by
PICS and with 4300 cleavage sites, greatly exceeds
the 2405 cleavage site identified by PICS for six type
II transmembrane serine proteases previously [50].
The present PICS data can guide small molecule drug
development and the interpretation of proteomic results
or other proteome-wide natural substrate identification
screens such as Terminal Amino Isotopic Labeling
of Substrates (TAILS) [76,77], which complements
PICS and other peptide approaches that do not identify
native substrates [48]. Thus, our compendium of
more than 4300 cleavage sites, supported by in-depth
peptide cleavageanddockingassays,will further assist
in the design of improved diagnostic assays and new
therapeutics guided by the identified differences in
specificity preferences.
PICS provides crucial in vitro information that can
be exploited to further understand biological roles
of MMPs in cleaving components of the ECM and
the signaling mediators regulating synthesis or
remodeling of the matrix: Specificity profiles can
be used to discriminate between direct and indirect
effects of a particular protease in the complex
dynamic interplay of proteases and inhibitors in the
protease web [24] and to distinguish between direct
and indirect targets of MMPs in N-terminomics
studies in vivo. However, despite their obvious
strengths, peptide-based approaches such as
PICS cannot be used for native substrate discovery
nor for the design of exosite-targeting inhibitors to
selectively impede the cleavage of a specific
substrate or a substrate subset [41,78,79]. The
complexity of the higher-order structures of matrix
proteins generated by intramolecular and intermo-
lecular interactions forming the complex intercon-
nected ECM renders many techniques of limited
use in discovering native substrates and hence
roles in ECM biology. For these more complex in
situ analyses, TAILS N-terminomics is the method
of choice as it is proven to successfully identify a
myriad of native substrates in complex connective
tissues and even in whole arthritic joints of MMP
knockout vs. wild-type mice [27] by quantitative
proteomic profiling [76,77]. Thus, these high
throughput analyses have revealed that ECM
components make up just 18% of MMP substrate
repertoires, with signalingmolecules, receptors and
other bioactive mediators in the matrix being more
highly represented substrates [6,20–23,26], a bigdeparture from when MMPs were considered mere
matrix remodelers [3,12].
Experimental procedures
Expression and purification of human MMPs
MMPs 1, 2, 3, 8, 9 and 13 were expressed from
vector pGW1HGand purified fromChinese hamster
ovary or Timp2−/− murine embryonic fibroblast cell-
conditioned medium [31,80,81], and soluble, se-
cretory MMP14 (pro-sMMP14) was purified from
Pichia pastoris as described elsewhere [82]. The
use of different expression and purification
schemes was necessary to accommodate the
individual needs of the respective MMP variants.
Active MMP7 was purchased from Enzo Life
Sciences (BML-SE181) and MMP12 was a kind gift
from Novartis Pharma AG (Basel, CH). Purity of MMPs
was assessed by Coomassie brilliant blue stained
SDS-PAGE (15% gels) analysis of 1–2 μg of each
MMP under reducing conditions, and using GeneDir-
eX'sPiNKPlusPrestainedProtein Ladder asmolecular
weight marker (Fig. 1C). Of note: the mammalian
expression vector used in this study (pGW1HG) was at
times inaccurately named pGW1GH or pGWIGH in
previous publications from our lab. ProMMPs were
activated in 100 mM Tris, pH 7.5, 100 mM NaCl,
10 mM CaCl
2
, and 0.05% Brij-35, using 1 mM para--
aminophenylmercuric acetate at 37 °C for 30 min.
Chymotrypsin was used for MMP3 activation (1:100
(w/w), 30 min, 37 °C) and was subsequently inacti-
vated by adding 1 mM PMSF.
PICSproteome-derivedpeptide library preparation
Human proteome-derived peptide libraries for MMP
assayswere preparedasdescribed [48,49].Cell pellets
collected from a human lymphoblast cell line K-562
(ATCC # CCL-243) were lysed in 20 mM Hepes,
pH 7.5, supplemented with 0.1% (w/v) SDS and
protease inhibitors (1× Roche cOmplete protease
inhibitor cocktail supplemented with 10 mM EDTA
and 1 mM PMSF), and centrifuged to remove cell
debris (26,000 ×g, 1 h, 4 °C). Proteins in the super-
natant were denatured with 4 M guanidine hydrochlo-
ride and cysteine side chains were reduced with
20 mM DTT (1 h, 37 °C) and then protected with
40 mM iodoacetamide (3 h, 20 °C). It is notable that
whereas most synthetic peptide libraries do not
incorporate cysteine, in PICS libraries cysteine is
present as a carbamidomethylated form. Cell lysate
proteins were subsequently purified by chloroform/
methanol precipitation [110], air-dried, re-suspended
in 100 mMHepes, 5 mMCaCl2, pH 7.5, and digested
with trypsin (TPCK treated, Sigma-Aldrich) or GluC
(S. aureus protease V8, Worthington) at a protease to
proteome ratio of 1:100 (w/w) for 16 h, 37 °C. After
54 Specificity portrayal of nine matrix metalloproteinasesdeactivation of trypsin or GluC with 1.0 mM PMSF
(30 min, 20 °C), N-terminal and lysine primary amines
were blocked by reductive dimethylation with 30 mM
formaldehyde and 15 mM sodium cyanoborohydride
(NaCNBH3, Sterogene) for 16 h at 20 °C. The
resulting peptides were desalted by size exclusion
chromatography (Sephadex G-10 columns, 10 mM
potassium phosphate buffer, pH 2.7, 10% (v/v)
methanol), and after methanol removal by vacuum
concentration (SpeedVac, Thermo), further purified by
reversed-phase chromatography (RESOURCE RPC
column, GE Healthcare; wash step with 0.3% (v/v)
formic acid; elution in 80% (v/v) acetonitrile). Eluates
were concentrated to a minimal volume by vacuum
concentration, re-suspended in water, and stored at
−80 °C as peptide libraries of 200 to 400 μg in
concentrations of 5 to 15 mg/ml. All reagents were
purchased from Sigma-Aldrich unless otherwise
specified.
PICS MMP assays and enrichment of prime side
cleavage products
PICS cleavage assays were performed by incu-
bation of 200 to 400 μg peptide library with active
recombinant MMP (Fig. 1C) at a protease to peptide
library ratio of 1:100 (w/w) in 50 mMHepes, 150 mM
NaCl and 5 mM CaCl2, pH 7.4. Importantly, the
proteome source has negligible influence on the
PICS result in our experience [76]. Cleaved peptides
presenting neo N-termini generated by MMP cleav-
age were biotinylated by incubation with 0.5 mM
Sulfo-NHS-SS-Biotin (amine-reactive biotinylation
reagent with a cleavable disulfide linker; Life
Technologies) for 2 h at ambient temperature.
Biotinylated prime side cleavage products were
affinity purified from uncleaved peptides by incuba-
tion with 300 μl streptavidin Sepharose slurry (GE
Healthcare) for 2 h at ambient temperature with mild
agitation. After extensive washing, biotinylated
peptides were eluted with 20 mM DTT (2 h, 22 °C)
and desalted using reversed-phase solid phase
extraction (Sep-Pak C18, Waters) with binding and
washing in 0.1% (v/v) formic acid and elution in 50%
(v/v) acetonitrile. The eluates were vacuum dried to
near dryness and stored at −80 °C prior to LC–MS/
MS analysis.
LC–MS/MS analysis and spectrum to sequence
assignment
Samples were analyzed by LC–MS/MS using a
LC Packing's capillary LC system (Dionex) coupled
online to a quadrupole time-of-flightmass spectrometer
(QSTARXL,AppliedBiosystems, operatedby theUBC
Centre for Blood Research Mass Spectrometry Suite,
or QSTAR Pulsar I, Applied Biosystems, operated
by the UBC Proteomics Core Facility). Samples were
diluted in 0.3% (v/v) formic acid and loaded onto acolumn packed with Magic C18 resin (Michrom
Bioresources). Peptides were eluted using a 2 to 80%
(v/v) gradient of organic phase over 95 min. Buffer A
was2% (v/v) acetonitrilewith 0.1% (v/v) formic acid and
buffer B was 80% (v/v) acetonitrile with 0.1% (v/v)
formic acid. MS/MS data were acquired automatically,
using the Analyst QS software, v1.1 (Applied Biosys-
tems) for information-dependent acquisition based ona
1 sMSsurvey scan from350m/z to 1500m/z, followed
by up to 3 MS/MS scans of 2 s each. Peak lists were
converted to themzXML format and peptides identified
from the human UniProtKB/Swiss-Prot database [83]
containing canonical and isoform protein sequences
(downloaded October 2013), using X!TANDEM [84] in
conjunction with PeptideProphet [85] as implemented
in the Trans Proteomic Pipeline v4.3 [86] at an
estimated false discovery rate of 1%. Search param-
eters included a mass tolerance of 200 ppm for the
parent ion and 0.2 Dalton (Da) for the fragment ions,
allowing up to two missed cleavages, and carbamido-
methylation of cysteine residues (+57.02 Da)
and dimethylation of lysine Ɛ-amines (+28.03 Da)
as fixed modifications. Methionine oxidation
(+15.99 Da), dimethylation (+28.03 Da) and thioacyla-
tion (+88.00 Da) of peptide N-termini were set as
variable.
LC–MS/MS data analysis
Peptides identified by MS/MS represent the prime
side MMP cleavage products. The complete cleav-
age sites were reconstructed using the open
web-based program WebPICS [87] (http://
clipserve.clip.ubc.ca/pics/). WebPICS generates a
non-redundant list of identified cleavage sites in
peptides by matching each non-redundant prime--
side peptide sequence to the human IPI database
(v3.69, 174,784 entries; EMBL-EBI, UK) [88] and
extracting the non-prime cleavage side sequence
up to the next cleavage site of the enzyme used for
library generation, i.e. to the next N-terminal Arg or
Lys in the case of trypsin-generated libraries or the
next N-terminal Asp or Glu for GluC-libraries.
Non-prime subsite positions with ambiguous infor-
mation coming from different protein isoforms are
omitted, but the prime-side sequence is still ana-
lyzed in the pool. Identified cleavage sites were
summarized as heat maps (Gnuplot; www.gnuplot.
info) showing relative occurrence and fold-change
over natural abundance of amino acids and as
iceLogos [89], displaying percent difference com-
pared to natural amino acid abundance. Of note,
PICS is not designed for substrate discovery; thus
provided UniProt identifiers in Supplementary Ta-
bles 1 and 2 are for reference only and do not
represent substrate candidates. All mass spectrom-
etry raw data have been deposited to ProteomeX-
change Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner
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bPXD002265N.
Quenched fluorescence protease activity assay
Stock solutions (1.0 mM) of synthetic quenched
fluorescence (QF) peptide substrates (ChinaPeptides
Co. Ltd., Shanghai, China) were dissolved in DMSO.
Working stocks (100 μM) were prepared in DMSO
using the molar extinction coefficient of the conjugated
quencher, (2,4)-dinitrophenyl, of 6.985 cm−1 mM−1 at
400 nm [91]. Fluorogenic protease-activity assays
were performed immediately after MMP activation in
the presence of protease inhibitor cocktail (HALT™,
Life Technologies, in the absence of EDTA) using a
multi-wavelength fluorescence scanner (POLARstar
OPTIMA, BMG Labtech). Each purified and activated
recombinantMMP (1–10 nM)was incubatedwith 1 μM
QF-peptide in 100 μl of 100 mM Tris, pH 7.5, 100 mM
NaCl, 10 mMCaCl2, and 0.05% Brij-35. The excitation
and emission wavelengths were set to 320 and
405 nm, respectively. The fluorescencewasmeasured
at 45 s intervals for 1 h at 37 °C. All measurements
were performed in duplicate. Experiments were repeat-
ed at least three times with independent substrate and
MMP preparations on different days.
In silico structural analysis of MMPs
Models of the catalytic domains of human MMPs
were generated using the following PDB entries and
domain boundaries: 2clt ( isolated MMP1,
F100-R262), 3ayu (MMP2 in complex with beta-a-
myloid precursor protein-derived inhibitory peptide,
Y110-A447), 1c3i (MMP3 complexed with a pro-
peptide-based inhibitor, F100-P265), 1mmq (MMP7
complexed with hydroxamate, carboxylate, and
sulfodiimine inhibitors, Y95-K260), 1bzs (isolated
MMP8, F99-L263), 4h3x (MMP9 complexed with a
hydroxamate-based inhibitor, F107-P445), 1jiz
(MMP12 in complex with a hydroxamic acid inhib-
itor, F100-D264), 2d1n (MMP13 with a hydroxamic
acid inhibitor, Y104-P268), and 1bqq (MMP14
complexed with TIMP2, Y112-G285) [75,92–99].
Missing terminal residues of MMP14 were modeled
using the SWISS-MODEL server with default
settings [100] and MMP12 (PDB ID: 1jiz) as
template to obtain a salt-bridge N-terminus to
Asp274; active site mutations were reverted within
PyMOL (The PyMOL Molecular Graphics System,
Version 1.7.1.3, Schrödinger, LLC) [101]. Second-
ary structures were assigned using KSDSSP [102]
and amino acid sequence numberings were cor-
rected within the UCSF Chimera package [103].
PDB files were converted into PQR files containing
per-atom charge and radius using the PDB2PQR
server [104] and PROPKA [105] to assign proton-
ation states at pH 7.4. Surface charge representa-
tions were created within PyMOL [101] using theAPBS Plug-in [106,107]. Peptide dockings with the
respective substrates were performed using the
high resolution Rosetta FlexPepDock server with
default settings [72]. All results were evaluated and
optimized based on the available complex structures
for the prime site and the anti-parallel edge strand for
non-prime substrate recognition. Total energies for the
obtained complexes were between −206.2 (MMP1
PLG↓L) and −288.0 (MMP13PAN↓L) Rosetta energy
units (REU), with an average of −253.6 REU and a
standard deviation of 32.2. The difference in total
energies within the top-10 models of each peptide
docking scenario wasminor, typically between 2.0 and
3.0 REUs, andwith 6–8 of the Rosetta top-10 solutions
following the same backbone trace and sidechain
orientation, of which one representative was chosen.
Integrity of the active site was checked manually for all
models. The topology representation was created
using TopDraw [108] within the CCP4 software suite
[109]. All other molecular graphics figures were made
using the molecular visualization system PyMOL.
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.matbio.2015.09.
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